High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer High Febrile Neutropenia Risk With Docetaxel in Prostate Cancer
The risk is high enough to consider routine febrile neutropenia prophylaxis in patients with metastatic castration-resistant disease. The study was published as a preprint and has not been peer reviewed.First Look
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Prostate Cancer | Study | Taxotere